John Cox (Credit: Repligen)
March 12, 2020 09:16 AM EDTUpdated 12:43 PM
Deals

Flag­ship merges two star­tups to build a $220M Reper­toire of T cell tech, ther­a­pies

Amber Tong

Senior Editor

Soon af­ter John Cox took over as CEO at Torque Ther­a­peu­tics, he reached out to Jose‑Car­los Gutiér­rez‑Ramos.

Gutiér­rez‑Ramos, who left Syn­log­ic in 2018 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times